Back to search

Article

Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML Patients

2023-04-29

Abstract excerpt

The traditionally dismal outcome of acute myeloid leukemia (AML) patients carrying the FMS-related tyrosine kinase 3 (FLT3) mutations has been mitigated by the recent introduction into the clinics of tyrosine kinase inhibitors (TKI) such as midostaurin and gilteritinib. The present work summarizes the clinical data that led to the use of gilteritinib in clinical practice. Gilteritinib is a 2nd generation TKI with...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2f55a7dd-8e6d-52ea-ab4d-e4d53a6c4b55
DOI
10.20944/preprints202304.1236.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Gilteritinib: The Story of a Proceeding Success into Hard-to-Treat FLT3 Mutated AML PatientsDOI 10.20944/preprints202304.1236.v1
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.Semantic proximity
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation.Semantic proximity
Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions.Semantic proximity
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.Semantic proximity
Gilteritinib: potent targeting of FLT3 mutations in AML.Semantic proximity
Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.Semantic proximity
FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation.Semantic proximity
Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.Semantic proximity
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.Semantic proximity
Gilteritinib: An FMS-like tyrosine kinase 3/AXL tyrosine kinase inhibitor for the treatment of relapsed or refractory acute myeloid leukemia patients.Semantic proximity
The European Medicines Agency Review of Gilteritinib (Xospata) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an FLT3 Mutation.Semantic proximity
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.Semantic proximity
Select a neighboring publication to make it the new centre.